Education
About Us
Working with TipRanks
Follow Us
GNOM - ETF AI Analysis
Top Page
Global X Genomics & Biotechnology ETF (GNOM)
Rating:63Neutral
Price Target:―
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered solid returns year-to-date, indicating strong momentum in the biotechnology sector.
Focused Health Care Exposure
Nearly all assets are invested in the health care sector, benefiting from the growth potential of genomics and biotechnology.
Top Holdings Showing Strength
Several top holdings, such as Guardant Health and Alnylam Pharma, have shown strong year-to-date performance, supporting the fund's overall gains.
Negative Factors
High Sector Concentration
The ETF is heavily concentrated in the health care sector, making it vulnerable to downturns in this industry.
Limited Geographic Diversification
The fund is overwhelmingly focused on U.S. companies, with minimal exposure to international markets.
Mixed Performance Among Holdings
Some top holdings, such as Illumina and Bio-Techne, have underperformed, which could drag on overall returns.
GNOM vs. SPDR S&P 500 ETF (SPY)
AUM52.40M
RegionGlobal
Expense Ratio0.50%
Beta1.19
IssuerGlobal X
Inception DateApr 05, 2019
Dividend Yield1.25%
Asset ClassEquity
Index TrackedSolactive Genomics Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume9,872
30 Day Avg. Volume10,735
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
62.36Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering49
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GNOM Summary
The Global X Genomics & Biotechnology ETF (ticker: GNOM) is an investment fund focused on companies leading the way in genomic research and biotechnology. It includes firms working on cutting-edge technologies like gene editing and personalized medicine. Some well-known companies in this ETF are Crispr Therapeutics and Illumina, both pioneers in healthcare innovation. Investors might consider GNOM for potential growth in the rapidly evolving genomics sector, which is reshaping medical treatments and diagnostics. However, new investors should be aware that this ETF is heavily tied to healthcare and biotechnology, meaning its performance can be sensitive to changes in these industries.
How much will it cost me?The Global X Genomics & Biotechnology ETF (GNOM) has an expense ratio of 0.50%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average because it is actively managed to focus on a specialized sector like genomics and biotechnology, which requires more research and expertise. It’s designed to give investors exposure to cutting-edge companies in this innovative field.
What would affect this ETF?The GNOM ETF, focused on genomics and biotechnology, could benefit from advancements in gene editing and personalized medicine, as well as increased global healthcare spending and innovation. However, it may face challenges from regulatory hurdles, high research costs, and potential market volatility in the healthcare sector. Its global exposure and top holdings in cutting-edge companies position it well for growth but also make it sensitive to changes in economic conditions and industry-specific risks.
GNOM Top 10 Holdings
The Global X Genomics & Biotechnology ETF (GNOM) is heavily concentrated in healthcare, with nearly all its holdings tied to genomic advancements. Illumina and Vertex Pharmaceuticals are steady performers, bolstered by strong earnings and strategic pipeline developments, while Arrowhead Pharmaceuticals is rising on clinical progress. However, Moderna and Qiagen are lagging, weighed down by financial challenges and valuation concerns. With a global focus, GNOM offers exposure to cutting-edge biotech innovation, but mixed stock performance highlights the sector’s inherent volatility and the need for patience from investors.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | 5.95% | $3.12M | $8.67B | 226.38% | 57 Neutral | |
| Moderna | 5.77% | $3.02M | $16.34B | 22.81% | 59 Neutral | |
| Guardant Health | 5.61% | $2.94M | $14.51B | 205.89% | 61 Neutral | |
| Illumina | 5.54% | $2.90M | $21.64B | 3.64% | 71 Outperform | |
| Praxis Precision Medicines | 5.51% | $2.89M | $8.69B | 349.74% | 58 Neutral | |
| Natera | 4.51% | $2.37M | $31.99B | 46.03% | 73 Outperform | |
| Bio-Techne | 4.09% | $2.14M | $10.70B | -9.44% | 64 Neutral | |
| BioMarin Pharmaceutical | 3.85% | $2.02M | $10.49B | -11.28% | 75 Outperform | |
| Vertex Pharmaceuticals | 3.81% | $2.00M | $111.98B | 4.59% | 78 Outperform | |
| Avidity Biosciences | 3.77% | $1.98M | $10.93B | 150.73% | 62 Neutral |
GNOM Technical Analysis
Positive
―
Price Trends
45.43
Positive
42.45
Positive
37.59
Positive
Market Momentum
0.70
Negative
58.58
Neutral
74.74
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GNOM, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 46.94, equal to the 50-day MA of 45.43, and equal to the 200-day MA of 37.59, indicating a bullish trend. The MACD of 0.70 indicates Negative momentum. The RSI at 58.58 is Neutral, neither overbought nor oversold. The STOCH value of 74.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GNOM.
GNOM Peer Comparison
Comparison Results
Performance Comparison
GNOM
Global X Genomics & Biotechnology ETF
47.81
8.45
21.47%
EVX
VanEck Environmental Services ETF
―
―
―
FFND
Future Fund Active ETF
―
―
―
VEGI
iShares MSCI Global Agriculture Producers ETF
―
―
―
IBLC
iShares Blockchain and Tech ETF
―
―
―
HELX
Franklin Genomic Advancements ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents